Boston Scientific study shows Precision Spectra SCS system efficacy

Boston Scientific has announced positive data from a new long-term study of its Precision Spectra spinal cord stimulator (SCS) system.

Presented at the 18th North American Neuromodulation Society annual meeting, the new findings from the PRO study demonstrate that the device provided sustained and highly significant relief for low back pain patients 12 months after implantation.

The outcomes review of 213 patients at 13 centres focused on patients with chronic pain and low back pain who are receiving treatment with the Precision Spectra SCS System. This cohort will now be followed through to a 24-month interval.

Key benefits of Precision Spectra include its Illumina 3D Software, an anatomy-driven computer model designed for simple point-and-click pain targeting, allowing the neural target to be stimulated without affecting undesired areas.

Maulik Nanavaty, president of neuromodulation at Boston Scientific, said: "This long-term, real-world study reflects our continuing commitment to advancing the science of pain relief to help achieve better outcomes for patients with chronic pain."

This comes after the company's Synergy everolimus-eluting coronary stent system was shown to have met its primary endpoint in pivotal US trial data announced last month.